EPISODE · Apr 15, 2024 · 8 MIN
New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376
from Pri-Med Podcasts · host Pri-Med
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376 Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes. Episode resource links: DM/HF: Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254 Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato
What this episode covers
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376 Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes. Episode resource links: DM/HF: Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254 Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato
NOW PLAYING
New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376
No transcript for this episode yet
Similar Episodes
Jun 15, 2022 ·8m
May 25, 2022 ·20m
May 19, 2022 ·16m
May 15, 2022 ·34m
May 12, 2022 ·1m